Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-03 CAR-T in R/R B-ALL
NCT06307600Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Mar 2024
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-RD06 in Acute B-cell lymphoblastic leukemia (B-ALL), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Dose-limiting toxicity at 2 years. Started Mar 2024; status: recruiting.
02
Drugs
CT-RD06
03
Conditions
Acute B-cell lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06307600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307600.